Advisory Services Network LLC Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Advisory Services Network LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 172.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,835 shares of the biotechnology company's stock after acquiring an additional 1,794 shares during the period. Advisory Services Network LLC's holdings in United Therapeutics were worth $1,000,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the fourth quarter valued at about $25,000. Millstone Evans Group LLC purchased a new position in United Therapeutics in the 4th quarter worth approximately $67,000. MassMutual Private Wealth & Trust FSB boosted its stake in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares during the period. Jones Financial Companies Lllp raised its position in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of United Therapeutics in the fourth quarter worth $131,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,500 shares of company stock worth $30,971,540. 11.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on UTHR shares. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday. Finally, UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Price Performance

Shares of UTHR stock traded down $0.46 during mid-day trading on Friday, hitting $284.73. The stock had a trading volume of 302,945 shares, compared to its average volume of 452,973. The firm has a market capitalization of $12.79 billion, a P/E ratio of 12.50, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 12-month low of $233.28 and a 12-month high of $417.82. The firm's 50-day moving average is $316.61 and its two-hundred day moving average is $348.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company posted $4.36 EPS. Analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.